Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP Vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
Conditions
Interventions
ASP0892 Intradermal
ASP0892 Intramuscular
+2 more
Locations
8
United States
Site US10014
Little Rock, Arkansas, United States
Site US10008
Mountain View, California, United States
Site US10001
Baltimore, Maryland, United States
Site US10002
Boston, Massachusetts, United States
Site US10004
New York, New York, United States
Site US10003
Chapel Hill, North Carolina, United States
Start Date
December 13, 2016
Primary Completion Date
December 6, 2018
Completion Date
December 6, 2018
Last Updated
October 23, 2024
NCT05695261
NCT03835767
NCT04222491
NCT04511494
NCT05424731
NCT03881696
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions